Cabot Wealth Management Inc. Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cabot Wealth Management Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,245 shares of the biopharmaceutical company’s stock, valued at approximately $207,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares during the last quarter. UMB Bank n.a. raised its position in Halozyme Therapeutics by 267.4% in the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 960 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $69,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.6%

HALO opened at $52.81 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51. The stock’s fifty day simple moving average is $56.73 and its 200 day simple moving average is $56.24. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The stock has a market cap of $6.51 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 0.35 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business had revenue of $264.86 million for the quarter, compared to analysts’ expectations of $231.21 million. During the same quarter in the prior year, the business earned $0.79 EPS. The firm’s revenue for the quarter was up 35.2% on a year-over-year basis. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director now directly owns 28,611 shares of the company’s stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HALO. Morgan Stanley lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $73.00 to $62.00 in a research report on Wednesday, May 14th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. upped their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. HC Wainwright reiterated a “buy” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Finally, Leerink Partners cut Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.